{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:30:43Z","timestamp":1761647443790},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,1,11]],"date-time":"2006-01-11T00:00:00Z","timestamp":1136937600000},"content-version":"vor","delay-in-days":5581,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm & Drug Disp"],"published-print":{"date-parts":[[1990,10]]},"abstract":"Abstract<\/jats:title>The bioavailability and pharmacokinetics of phenylpropanolamine hydrochloride (PPA HCl) from a Dexatrim\u00ae controlled\u2010release (CR) caplet and solution was studied. Each subject (n<\/jats:italic> = 12) received either a 75 mg PPA HCl CR caplet once daily or a 25 mg PPA HCl solution given three times a day. All subjects received the medication for 4 consecutive days. On Day 1, the mean \u00b1 SEM, AUC, t<\/jats:italic>max<\/jats:sub>, and C<\/jats:italic>max<\/jats:sub> values were 1651 \u00b1 127 ng x h ml\u22121<\/jats:sup>, 4\u00b75 \u00b1 0\u00b726 h and 143 \u00b1 13\u00b75 ng ml\u22121<\/jats:sup>, respectively, for the CR caplet and 1716 \u00b1 90\u00b73ng \u00d7 h ml\u22121<\/jats:sup>, 1\u00b725 \u00b1 0\u00b708 h and 126 \u00b1 5\u00b78 ng ml\u22121<\/jats:sup> for the solution, respectively. At steady state (Day 4), the mean \u00b1 SEM, AUC, t<\/jats:italic>max<\/jats:sub>, and C<\/jats:italic>max<\/jats:sub> values were 1832 \u00b1 101 ng x h ml\u22121<\/jats:sup>, 4\u00b717 \u00b1 0\u00b717 h and 151 \u00b1 6\u00b75 ng ml\u22121<\/jats:sup>, respectively, for the CR caplet and 2014 \u00b1 116 ng x h ml\u22121<\/jats:sup>, 1\u00b733 \u00b1 0\u00b709 h and 143 \u00b1 8\u00b77 ng ml\u22121<\/jats:sup>, respectively, for the solution. The data from Day 1 were fitted to an oral one compartment model with a first order absorption rate constant, k<\/jats:italic>A<\/jats:sub>, first order elimination rate constant, k<\/jats:italic> and lag time. The mean \u00b1 SEM, k<\/jats:italic>A<\/jats:sub>, elimination half\u2010life and lag time for PPA HCl from the CR caplet were 0\u00b7488 \u00b1 0\u00b7182 ng h ml\u22121<\/jats:sup>, 5\u00b784 \u00b1 1\u00b766 h and 0\u00b7394 \u00b1 0\u00b7224 h, respectively. The mean \u00b1 SEM, k<\/jats:italic>A<\/jats:sub>, elimination half\u2010life and lag time for PPA HCl from the solution were 2\u00b787 \u00b1 1\u00b751 ng x h ml\u22121<\/jats:sup>, 3\u00b773 \u00b1 1\u00b721 h, and 0\u00b7325 \u00b1 0\u00b7101 h. respectively. The smaller apparent k<\/jats:italic>A<\/jats:sub> and longer elimination half\u2010life for PPA HCl from the CR caplet is due to the slow release of PPA HCl, thereby slowing its absorption producing sustained plasma drug concentrations. Blood pressures (supine and sitting) and heart rates measured at the time of blood sampling after the administration of the PPA HCl dosage forms demonstrated no clinically significant relationship between cardiovascular response and PPA HCl plasma concentration. These data demonstrate the bioavailability and pharmacokinetics of PPA HCl from a CR caplet and an immediate release solution.<\/jats:p>","DOI":"10.1002\/bdd.2510110703","type":"journal-article","created":{"date-parts":[[2006,10,14]],"date-time":"2006-10-14T12:23:30Z","timestamp":1160828610000},"page":"569-583","source":"Crossref","is-referenced-by-count":5,"title":["Bioavailability and cardiovascular safety of dexatrim\u00ae (phenylpropanolamine hydrochloride) from a controlledrelease caplet"],"prefix":"10.1002","volume":"11","author":[{"given":"Leon","family":"Shargel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold I.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peri","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,11]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Phenylpropanolamine. A Critical Analysis of Reported Adverse Reactions and Overdosage","author":"Morgan J. P.","year":"1985"},{"key":"e_1_2_1_3_2","volume-title":"Phenylpropanolamine. Risks. Benefits and Controversies","author":"Morgan J. P.","year":"1985"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1987.tb03089.x"},{"key":"e_1_2_1_5_2","first-page":"62","volume":"109","author":"Axelrod J.","year":"1973","journal-title":"J. Pharmacol. Expt. Ther."},{"key":"e_1_2_1_6_2","first-page":"139","volume":"162","author":"Wilkinson G. R.","year":"1968","journal-title":"J. Pharmacol. Expt. Ther."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj1360763"},{"key":"e_1_2_1_8_2","first-page":"153","volume":"220","author":"Thiercelin J. F.","year":"1976","journal-title":"Arch. Int. Pharmacodyn."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510080509"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600500313"},{"key":"e_1_2_1_11_2","first-page":"39","volume":"22","author":"Lonnerholm G.","year":"1984","journal-title":"Int. J. Clin. Pharmacol. Ther. Tox."},{"key":"e_1_2_1_12_2","first-page":"640","volume":"30","author":"Barrett W. E.","year":"1981","journal-title":"Curr. Ther. Res."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(87)90209-2"},{"key":"e_1_2_1_14_2","unstructured":"Metropolitan Life Insurance Bulletin 1983 64 1"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/01483918508067159"},{"key":"e_1_2_1_16_2","volume-title":"PC NONLIN","author":"Metzler C. M.","year":"1986"},{"key":"e_1_2_1_17_2","volume-title":"Introduction to Statistical Analysis","author":"Dixon W. J.","year":"1969"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.87"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(88)90008-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808802200403"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.153"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.253.17.2491"},{"key":"e_1_2_1_23_2","first-page":"746","volume":"17","author":"Saltzman M. B.","year":"1983","journal-title":"Drug Intel. Clin. Pharm."},{"key":"e_1_2_1_24_2","first-page":"185","volume":"28","author":"Silverman H. I.","year":"1980","journal-title":"Curr. Ther. Res."}],"container-title":["Biopharmaceutics & Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2510110703","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2510110703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T13:25:24Z","timestamp":1697981124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2510110703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1990,10]]}},"alternative-id":["10.1002\/bdd.2510110703"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2510110703","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,10]]}}}